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A CONSIDERATION OF ETHICAL AND LEGAL ISSUES
IN MULTI-SITE STUDIES
Sana Loue*
Abstract: Significant ethical and legal issues may arise in conjunction with the conduct of multi-site studies. For
example, different cultures may have varying concepts of personhood. The United States, for instance, places signifi-
cant emphasis on the autonomy of each individual, while many other societies rely to a greater degree on defining an
individual with reference to his or her roles or relationships to others. These differing orientations may have implica-
tions for informed consent procedures and for the design of procedures to maintain confidentiality of the data and
privacy of the participants. The development of procedures for the maintenance of confidentiality and privacy must
also consider any differences in reporting requirements between the sites that relate to sexually transmitted diseases and
child abuse. The implications of such differences for the conduct of multi-site studies are examined.
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CONSIDERACIÓN DE LOS TEMAS ÉTICOS Y LEGALES EN LOS ESTUDIOS
MULTICÉNTRICOS
Resumen: En relación con los estudios multicéntricos pueden surgir aspectos  éticos y legales. Por ejemplo, culturas
diferentes tienen conceptos distintos sobre las personas. Así, Estados Unidos enfatiza la autonomía del individuo,
mientras que otras sociedades definen, en mayor grado, al individuo según sus roles o su relación con los demás. Estas
orientaciones diferentes pueden influir en el proceso de obtener consentimiento informado y en el diseño de
procedimientos para mantener la confidencialidad de los datos y la privacidad de los participantes. El desarrollo de
procedimientos que garanticen la confidencialidad y la privacidad  debe considerar, también, cualquiera diferencia
entre los centros al informar los requisitos que  tengan relación con enfermedades de transmisión sexual  y con abuso de
niños. Se examinan las inferencias de estas diferencias al realizar estudios multicéntricos.
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CONSIDERAÇÃO DOS TEMAS  ÉTICOS E LEGAIS NOS ESTUDOS
MULTICÊNTRICOS
Resumo: Nos estudos multicêntricos surgem questões éticas e legais. Por exemplo, culturas diferentes tem conceitos
distintos sobre as pessoas. Assim, nos Estados Unidos enfatiza-se a autonomia do indivíduo, enquanto que em outras
sociedades definem, em maior ou menor grau, o indivíduo segundo seus papéis e sua relação com os demais. Essas
diferentes orientações podem influir no processo de obtenção do consentimento informado e no desenho de procedimentos
para manter a confidencialidade dos dados e a privacidade dos participantes. O desenvolvimento de procedimentos que
garantem a confidencialidade e a privacidade deve levar em conta, também, qualquer diferença entre os centros ao
informar os requisitos que tenham relação com as enfermidades de  transmissão sexual e com abuso de crianças. As
interferências destas diferenças nos estudos multicêntricos são analisadas.
Palavras chave: Estudos multicêntricos, confidencialidade
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Introduction
In order to ensure that results are valid across
the various sites of a multi-site study, it is im-
portant that, to the greatest extent possible, pro-
cedures across all sites be identical. This in-
cludes not only any interventions that may be
part of the study, but recruitment and consent
procedures as well. The 2002 revision of
CIOMS’ International Ethical Guidelines for
Biomedical Research Involving Human Sub-
jects1 explains in a commentary to Guideline 4
the parameters of the informed consent process:
“Obtaining informed consent is a process
that is begun when initial contact is made with
a prospective subject and continues through-
out the course of the study. By informing the
prospective subjects, by repetition and expla-
nation, by answering their questions as they
arise, and by ensuring that each individual un-
derstands each procedure, investigators elicit
their informed consent and in so doing mani-
fest respect for their dignity and autonomy.
Each individual must be given as much time as
is needed to reach a decision, including time
for consultation with family members or oth-
ers. Adequate time and resources should be set
aside for informed-consent procedures.”
As part of this process, investigators must
provide to participants during the informed
consent process information about any limits
to their ability to protect the confidentiality of
the data to be collected and the potential con-
sequences of any breach of that confidentiality
(Guideline 5).
This article reviews issues related to the
preservation of confidentiality and the use of
certificates of confidentiality that may arise in
the context of multi-site studies.
Certificates of Confidentiality
Numerous mechanisms exist for safeguard-
ing study data once it has been collected. These
include, for instance, omitting information that
might reveal the identity of the participant and
limiting access to information by using pass-
words on computers, keys for filing cabinets
and offices. In the United States, certificates of
confidentiality may also be available to limit
external access to study data. However, because
similar mechanisms may not exist in jurisdic-
tions outside of the United States, legal and ethi-
cal issues related to the maintenance of confi-
dentiality may arise.
Certificates of confidentiality are issued by
the National Institutes of Health to protect the
confidentiality of research data by protecting
investigators and institutions from being com-
pelled to release information about the study
participants. Authority for the issuance of cer-
tificates of confidentiality arises from section
301(d) of the Public Health Service Act, which
provides that the Secretary of Health and Hu-
man Services may authorize individuals en-
gaged in biomedical, behavioral, clinical, or
other research to protect the privacy of indi-
viduals who are the subjects of that research.
This authority has been delegated to the Na-
tional Institutes of Health.
A certificate of confidentiality, as indicated,
allows researchers to avoid the involuntary dis-
closure of data that could identify either directly
or indirectly an individual, such as through a
court order. “Identifying characteristics” refers
to such things as name, address, social security
number, fingerprints, voiceprints, photographs,
and genetic information such as DNA. If a cer-
tificate of confidentiality is obtained, the study
participants must be told of this. However, the
fact that there is a certificate in place to protect
confidentiality may not be used to coerce indi-
viduals to participate in the study.
1 Council of International Organizations of Medical Sciences.
International Ethical Guidelines for Biomedical Research
Involving Human Subjects. Geneva: CIOMS; 2002.
Acta Bioethica  2004; año X, nO 1
71
The certificate does not protect against vol-
untary disclosures by the investigator, such as
in cases of child abuse, reportable sexually
transmitted diseases, and the disclosure of in-
formation pursuant to audit requirements by the
funding entity. If the investigator wishes to re-
tain the ability to disclose voluntarily such
things as child abuse, he or she must advise the
participant of this in the informed consent docu-
ments. The certificate still allows the partici-
pant to consent to the disclosure of specified
information, if he or she wishes to do so.
A certificate of confidentiality is available
only for research that is considered to be sensi-
tive. This includes research that involves the
collection of information related to genetics; the
psychological well-being of individuals; sexual
attitudes, preferences, and behaviors; substance
abuse and other illegal behaviors; and exposures
that may be the focus of litigation, such as pes-
ticide exposures. Sensitive information could
be defined as information that could damage
an individual if it were to be released or could
result in discrimination or stigmatization of that
individual in his or her community. One ex-
ample is that of research on the transmission of
HIV and other sexually transmitted disease.
Certificates can be issued for single site
projects and for multi-site projects as well. In
order to obtain a certificate for a multi-site
study, each participating unit, together with its
address and the name of its director, must be
indicated. The lead site of a multi-site study
must indicate that it has a copy of the approval
of the study and the consent form from the in-
stitutional review board at each site. NIH fund-
ing for the project is not required in order to
obtain a certificate.
Some types of projects are not eligible for a
certificate of confidentiality. This includes
projects that are not research, projects that do
not include the collection of personally identi-
fying information, projects that have not been
reviewed and approved by an institutional re-
view board as required by the guidelines for
certificates, and projects that are collecting in-
formation that, if disclosed, would not signifi-
cantly harm or damage the individual to whom
the information pertains.
In order to apply for a certificate of confi-
dentiality, the investigator must provide the
following information to the appropriate insti-
tute of the National Institutes of Health: the
name and address of the research institution,
the title of the research project, the sites where
the research is to be conducted, the source and
number of the supporting grant, documentation
of approval from the appropriate institutional
review board or boards and the qualifications
of these boards, the contact information for the
principal investigator and other key personnel,
a summary of the scientific training of all key
personnel, the beginning and ending dates of
the research, a description of the research and
the study procedures, a description of means
used to protect the participants’ identity, the
reasons for requesting a certificate of confiden-
tiality, and copies of the informed consent forms
approved by the appropriate institutional review
boards. In addition, the applicant investigator
and the appropriate official from his or her in-
stitution must sign a letter containing prescribed
verbiage that indicates that the investigator and
institution will defend the certificate against any
legal attack if challenged.
Consider the following examples of studies
in which the protections of a certificate of con-
fidentiality might be important.
• An HIV-vaccine trial is being conducted in
several countries. As part of the study, the
investigators must collect data on sexual
behavior. In one of the countries in which
the study is being conducted, homosexual-
ity is stigmatizing, but is not illegal. In a
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second country, homosexuality is illegal and
may result in imprisonment. In the third
country site, homosexuals have almost the
same legal rights as heterosexuals.
• A study is investigating an intervention to
reduce the transmission of sexually trans-
mitted diseases among women who are at
high risk. Commercial sex workers are en-
rolled into the study.  In one country, prosti-
tution is legal if the individual is registered
and has a permit. However, all instances of
sexually transmitted diseases must be re-
ported to the licensing authority, which will
then revoke the permit. Anecdotal reports
indicate that those reported to be infected
with HIV have been killed by individuals in
the community, although information relat-
ing to their permits is supposed to remain
confidential. At the second site, in another
country, commercial sex work is illegal and
those engaged as commercial sex workers
are subject to imprisonment and potentially
face the loss of their children.
• A study is investigating the genetic causes
of schizophrenia. At one site, individuals are
able to obtain medical care through a so-
cialized medical system. Consequently, they
will not experience a loss of care due to a
diagnosis of schizophrenia, but may be so-
cially stigmatized. In contrast, at the second
site, individuals are able to access their
choice of care based upon their ability to
pay, which often depends on whether or not
they have private health care insurance.
They could potentially be disqualified from
receiving insurance benefits if they were
found to be genetically susceptible to
chronic disease, such as schizophrenia.
Several critical issues are raised if certificates
of confidentiality or a similar mechanism to pro-
tect the confidentiality of the data and the pri-
vacy of the participants are not available across
all sites of a study. First, how does the availabil-
ity of these protections differentially impact re-
cruitment and retention across all sites? Second,
does the existence of these protections at some,
but not all, of the participating sites in a multi-
site study result in significant variation of the
risk-benefit ratio across the sites and, if it does,
how can this be remedied?
The answer to the first question is, at the
present time, unknown. No studies have been
conducted on what participants understand
about certificates of confidentiality or how the
existence of a certificate might influence their
decision to participate in a study. It is possible,
for instance, that the existence of a certificate
and the apparently heightened confidentiality
protections would not carry any significance for
the participants. However, the possession of a
certificate and its additional protections may be
critical to recruitment and retention efforts in
instances where participants are particularly
vulnerable due to a potentially stigmatizing
characteristic or illegal behavior. Research re-
lating to the impact of certificates of confiden-
tiality would help to clarify this issue and may,
in fact, be critical to understand if the risk-ben-
efit ratio varies across sites.
The answer to the second question is unclear.
In order for the risk-benefit ratio to be different
as a result of the certificate of confidentiality,
the certificate must actually be effective in pre-
cluding access to information that would iden-
tify an individual study participant. Even in the
United States, where the certificates are avail-
able and in use, their present effectiveness is
unclear.  In 1973, a New York State appeals court
upheld the refusal of a substance use program
director to provide, as ordered by a court, iden-
tifying information about program participants2.
The program director refused to produce the re-
quested information based on assurances from
2 People v. Newman, 32 N.Y. 2d 379 (1973).
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then-existing federal Department of Health and
Welfare that the data had a guarantee of abso-
lute confidentiality pursuant to the then-exist-
ing statutes3, 4. These statutes provided that the
Secretary of the Department of Health and Wel-
fare and the United States Attorney General were
empowered to authorize persons “engaged in
research on the use and effect of drugs” to  “pro-
tect the privacy of [the research participants]”
by withholding their “names or other identify-
ing characteristics” from anyone not associated
with the research program5 . Such authorized
persons could not “be compelled in any Federal,
State, or other local, civil, criminal, administra-
tive, legislative or other proceedings” to iden-
tify the research participants6 . The appeals court
held that federal law regarding the confidential-
ity of these data preempted any state provisions
that might permit access. Whether the courts to-
day would also uphold the use of the certificate
of confidentiality to preclude access to identify-
ing characteristics is unclear, in view of subse-
quent changes in the statutory language and the
enactment of other laws that might reflect com-
peting interests, such as laws aimed at the iden-
tification of individuals believed to be associ-
ated with terrorist efforts.
Realistically, the risk-benefit ratio may vary
for groups of participants by virtue of the dif-
fering conditions across study sites, regardless
of the existence of a certificate of confidential-
ity.  For example, individuals who do not have
access to health care outside of the context of a
research study may perceive more benefits to
their participation than those at a different site,
who have access to health care routinely due to
the nature of the health care infrastructure.
Consistency in the study protocol across all sites
cannot be interpreted to necessitate consistency
in all circumstances. Unlike the situation in-
volving health care, however, reliance on a cer-
tificate of confidentiality represents a variation
in the actual study procedures and protections.
Assuming that the certificate would be up-
held and that a resulting difference in the risk-
benefit ratio must be addressed, several poten-
tial solutions may be available. First, it may be
possible to negotiate, in the context of specific
studies, an agreement between the study sites
and concerned legal and administrative entities
to provide confidentiality protection to the same
degree that would be provided as if there were a
certificate of confidentiality in place. This would
entail fairly complex negotiations involving
multiple entities and would provide protection
only for the specified study or studies.
A second, broader approach would require
the development of an agreement between the
country or countries sponsoring the research and
the sites at which the research is to occur. This
approach would require cooperation and collabo-
ration at multiple levels of government, in addi-
tion to any institutional agreements. Each of these
potential approaches, however, will require con-
siderable examination and negotiation.
3 42 U.S.C. § 242a.
4 21 U.S.C. § 872.
5 42 U.S.C. § 242a.
6 Ibid.
